Overview

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

Status:
Active, not recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
PH-HFpEF patients will receive weekly open-label doses of levosimendan and be periodically evaluated for safety and effectiveness in extended use.
Phase:
Phase 2
Details
Lead Sponsor:
Tenax Therapeutics, Inc.
Treatments:
Pharmaceutical Solutions
Simendan